Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.

TitleCirculating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
Publication TypeJournal Article
Year of Publication2017
AuthorsGraff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A
JournalProstate
Volume77
Issue6
Pagination647-653
Date Published2017 May
ISSN1097-0045
KeywordsAdult, Aged, Aged, 80 and over, Antioxidants, Biomarkers, Tumor, Case-Control Studies, Double-Blind Method, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Prostatic Neoplasms, Risk Factors, Serine Endopeptidases, Transcriptional Regulator ERG
Abstract

BACKGROUND: Few studies have considered etiological differences across molecular subtypes of prostate cancer, despite potential to improve opportunities for precision prevention of a disease for which modifiable risk factors have remained elusive. Factors that lead to DNA double-strand breaks, such as oxidative stress, may promote the formation of the TMPRSS2:ERG gene fusion in prostate cancer. We tested the hypothesis that increasing levels of pre-diagnostic circulating antioxidants, which may reduce oxidative stress, are associated with lower risk of developing TMPRSS2:ERG positive prostate cancer.

METHODS: We conducted a nested case-control study, including 370 cases and 2,470 controls, to evaluate associations between pre-diagnostic α- and β-carotene, α- and γ-tocopherol, β-cryptoxanthin, lutein, lycopene, retinol, and selenium with the risk of prostate cancer by ERG protein expression status (a marker of TMPRSS2:ERG). Multivariable unconditional polytomous logistic regression was used to calculate odds ratios and 95% confidence intervals.

RESULTS: We did not find any of the antioxidants to be significantly associated with the risk of prostate cancer according to ERG status.

CONCLUSIONS: The results do not support the hypothesis that circulating pre-diagnostic antioxidant levels protect against developing TMPRSS2:ERG positive prostate cancer. Additional studies are needed to explore mechanisms for the development of TMPRSS2:ERG positive disease. Prostate 77: 647-653, 2017. © 2017 Wiley Periodicals, Inc.

DOI10.1002/pros.23312
Alternate JournalProstate
PubMed ID28102015
PubMed Central IDPMC5354965
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
P01 CA087969 / CA / NCI NIH HHS / United States
R25 CA112355 / CA / NCI NIH HHS / United States
T32 CA009001 / CA / NCI NIH HHS / United States
UM1 CA167552 / CA / NCI NIH HHS / United States
R01 CA136578 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700